Autolus Therapeutics (AUTL) Aandelenoverzicht
Autolus Therapeutics plc, een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt T-celtherapieën voor de behandeling van kanker en auto-immuunziekten in het Verenigd Koninkrijk en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
AUTL Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Autolus Therapeutics plc Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$1.70 |
| 52 Week Hoogtepunt | US$2.70 |
| 52 Week Laag | US$1.18 |
| Bèta | 1.93 |
| 1 maand verandering | 18.06% |
| 3 maanden verandering | -6.59% |
| 1 Jaar Verandering | 10.39% |
| 3 jaar verandering | -39.93% |
| 5 jaar verandering | -74.36% |
| Verandering sinds IPO | -93.20% |
Recent nieuws en updates
Narratiefupdate • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.
Narratiefupdate • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.Narratiefupdate • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Recent updates
Narratiefupdate • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.Narratiefupdate • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.Narratiefupdate • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Narratiefupdate • Mar 31
AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Seeking Alpha • Mar 27
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking AlphaAnalyseartikel • Feb 03
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Dec 20
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...Nieuw narratief • Aug 17
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.Analyseartikel • Apr 04
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Seeking Alpha • Mar 04
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Autolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking AlphaAnalyseartikel • Jan 07
Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 21
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking AlphaAnalyseartikel • Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 31
Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 14
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking AlphaAnalyseartikel • Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyseartikel • Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendement voor aandeelhouders
| AUTL | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -5.6% | 2.4% | 1.1% |
| 1Y | 10.4% | 34.6% | 28.7% |
Rendement versus industrie: AUTL presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 34.6 % opleverde.
Rendement versus markt: AUTL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.7 % opleverde.
Prijsvolatiliteit
| AUTL volatility | |
|---|---|
| AUTL Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: AUTL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van AUTL is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2014 | 753 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt T celtherapieën voor de behandeling van kanker en auto-immuunziekten in het Verenigd Koninkrijk en internationaal. Het bedrijf biedt AUCATZYL, een gentherapieproduct dat bestaat uit autologe T-cellen die getransduceerd zijn met een lentivirale vector om een nieuwe anti-CD19 chimere antigen receptor tot expressie te brengen. Het ontwikkelt ook obe-cel, dat zich in fase 1 bevindt voor de behandeling van systemische lupus erythematosus, progressieve multiple sclerose, B-NHL en CLL, en CNS-lymfoom; obe-cel, dat zich in fase 2 bevindt voor de behandeling van pediatrische B-ALL en lupus nefritis; AUTO1/22 voor de behandeling van pediatrische B-ALL, dat zich in fase 1 bevindt; AUTO8, in fase 1 voor de behandeling van multipel myeloom en amyloïdose met lichte keten; AUTO4/5, in preklinische fase voor de behandeling van perifeer TCL; AUTO6NG, in fase 1 voor de behandeling van neuroblastoom; en AUTO9, in preklinische fase voor de behandeling van acute myeloïde leukemie.
Autolus Therapeutics plc Samenvatting
| AUTL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$452.44m |
| Inkomsten(TTM) | -US$288.96m |
| Inkomsten(TTM) | US$92.62m |
4.9x
P/S-verhouding-1.6x
Koers/WinstverhoudingIs AUTL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AUTL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$92.62m |
| Kosten van inkomsten | US$208.48m |
| Brutowinst | -US$115.85m |
| Overige uitgaven | US$173.11m |
| Inkomsten | -US$288.96m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.09 |
| Brutomarge | -125.08% |
| Nettowinstmarge | -311.98% |
| Schuld/Eigen Vermogen Verhouding | 325.9% |
Hoe presteerde AUTL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 21:10 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Autolus Therapeutics plc wordt gevolgd door 17 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |